Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2014

View Archived Issues

Gilead Sciences begins phase Ib study of GS-9883

Intra-Cellular Therapies and Takeda terminate collaboration to develop PDE1 inhibitors

Single nucleotide mutation in NFIA gene leads to brain malformation and urinary tract defect

Eisai advances pipeline in second quarter of fiscal 2014

Chemically attenuated whole parasite blood-stage malaria vaccine approach tested in humans

IntelGenx completes pilot study of INT-0036 for schizophrenia

Protection against T. cruzi observed with ArtinM in an acute experimental infection model

Affinivax launched with funding from Bill & Melinda Gates Foundation

Altor BioScience begins development of ALT-803 for multiple myeloma

Asana BioSciences reports discovery of kinase inhibitors for cancer

OncoArendi Therapeutics discloses new cancer treatments

Sage Therapeutics synthesizes novel GABA(A) receptor modulators

Amgen reports topline secondary endpoint results from TRINOVA-1 trial

D-Pharm reports data from phase II study of THR-18 in stroke patients treated with tPA

Ruga Corp. patents new B-raf kinase inhibitors

Chinese researchers prepare and test MKK1 inhibitors

Bayer completes acquisition of Dihon Pharmaceutical Group

NicOx reports development of NO donors

Repurposing of an approved glaucoma drug for the treatment of type 2 diabetes

CXCL10 gene polymorphism associated with malaria susceptibility in Ghanaian children

MedImmune to acquire tissue biomarker analysis company

EMA accepts Oleogel-S10 MAA for review

Terumo applies for approval of skeletal myoblast sheets

Kancera selects first candidate in ROR project

USAMRIID demonstrates in vitro activity of two HemispheRx drugs against Ebola virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...